RxDoctor Payments Data

John Mazur, MD

Pulmonary Disease · Great Falls, MTNPI 1659364651

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (42.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Intuitive Surgical at 46.7% of the total. 2025 is the largest year on record at $9,052, 7.9 times the $1,149 reported in 2019. Among pulmonary disease clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,530in general payments, 2019–2025

Across 296 payments — averaging $59.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • Pulmonx Corporation$3K
  • AstraZeneca$1K
  • Actelion Pharmaceuticals US, Inc.$966
  • GSK$795
  • Mallinckrodt Hospital Products Inc.$454
  • plus $3K from 29 others

What the payments were for

  • Travel & lodging$3,83222%
  • Food & beverage$6,28336%
  • Education$7,41542%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,530 in reported general payments places this provider in the 95th percentile of 43 pulmonary disease providers in Montana.

See all pulmonary disease providers in Montana

Medicare billing

Part B allowed, 2024
$280,390
Medicare patients
372
Services billed
4,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan46$584,329
Trelegy ElliptaFluticasone/Umeclidin/Vilanter299$269,913
Stiolto RespimatTiotropium Br/Olodaterol Hcl226$138,606
Breztri AerosphereBudesonide/Glycopyr/Formoterol160$115,157
Breo ElliptaFluticasone/Vilanterol142$81,760
Spiriva RespimatTiotropium Bromide97$64,159
Dupixent PenDupilumab14$54,842
Pirfenidone52$54,817
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr95$52,857
Advair HfaFluticasone Propion/Salmeterol98$37,330
DuleraMometasone/Formoterol45$15,200
SymbicortBudesonide/Formoterol Fumarate27$13,098
EliquisApixaban19$10,629
Arnuity ElliptaFluticasone Furoate39$9,010
Bevespi AerosphereGlycopyrrolate/Formoterol Fum15$7,964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$966$584,32946 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$795$417,494587 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$316$202,765323 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$1,183$136,219202 claims
MerckDulera$413$15,20045 claims
PfizerEliquis$18$10,62919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 pulmonary disease providers in Montana.

Other pulmonary disease in Great Falls

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →